MX2009010162A - Metodo para tratar dolor mediado por el receptor cb2. - Google Patents

Metodo para tratar dolor mediado por el receptor cb2.

Info

Publication number
MX2009010162A
MX2009010162A MX2009010162A MX2009010162A MX2009010162A MX 2009010162 A MX2009010162 A MX 2009010162A MX 2009010162 A MX2009010162 A MX 2009010162A MX 2009010162 A MX2009010162 A MX 2009010162A MX 2009010162 A MX2009010162 A MX 2009010162A
Authority
MX
Mexico
Prior art keywords
treating
receptor mediated
mediated pain
subject
pain
Prior art date
Application number
MX2009010162A
Other languages
English (en)
Inventor
Mark J Macielag
Christopher M Flores
Mingde Xia
Kevin Paul Pavlick
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010162(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009010162A publication Critical patent/MX2009010162A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención está dirigida a un método para tratar, mejorar o prevenir dolor mediado por el receptor CB2 en un sujeto que necesita del mismo, que comprende administrar al sujeto una cantidad efectiva de un compuesto de fórmula (I): (ver fórmula (I)) o una forma del mismo, en donde X1R1, X2R2, X3R3, X4R4 y X5R5 son como se definen en la presente.
MX2009010162A 2007-03-21 2008-02-27 Metodo para tratar dolor mediado por el receptor cb2. MX2009010162A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89601407P 2007-03-21 2007-03-21
PCT/US2008/055084 WO2008115671A1 (en) 2007-03-21 2008-02-27 Method for treating cb2 receptor mediated pain

Publications (1)

Publication Number Publication Date
MX2009010162A true MX2009010162A (es) 2009-10-12

Family

ID=39766329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010162A MX2009010162A (es) 2007-03-21 2008-02-27 Metodo para tratar dolor mediado por el receptor cb2.

Country Status (14)

Country Link
US (1) US20080234347A1 (es)
EP (1) EP2139326A4 (es)
JP (1) JP2010522181A (es)
KR (1) KR20090120499A (es)
CN (1) CN101677556A (es)
AR (1) AR065800A1 (es)
AU (1) AU2008229264A1 (es)
CA (1) CA2681381A1 (es)
CL (1) CL2008000827A1 (es)
MX (1) MX2009010162A (es)
PE (1) PE20090062A1 (es)
TW (1) TW200901972A (es)
UY (1) UY30973A1 (es)
WO (1) WO2008115671A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653127B2 (en) * 2009-01-28 2014-02-18 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CA3048926A1 (en) * 2017-11-15 2019-05-23 Panag Pharma Inc. Methods for treatment of interstitial cystitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
RS52195B (en) * 2005-09-23 2012-10-31 Janssen Pharmaceutica N.V. MODULATOR HEXA HYDROCYCLOHEPTAPIRAZOLE Cannabinoids

Also Published As

Publication number Publication date
EP2139326A1 (en) 2010-01-06
CA2681381A1 (en) 2008-09-25
JP2010522181A (ja) 2010-07-01
US20080234347A1 (en) 2008-09-25
AR065800A1 (es) 2009-07-01
CL2008000827A1 (es) 2008-09-26
UY30973A1 (es) 2008-09-30
AU2008229264A1 (en) 2008-09-25
CN101677556A (zh) 2010-03-24
EP2139326A4 (en) 2011-06-15
PE20090062A1 (es) 2009-01-26
WO2008115671A1 (en) 2008-09-25
KR20090120499A (ko) 2009-11-24
TW200901972A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
MX2009005649A (es) Tratamiento para mieloma multiple.
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MY158994A (en) Ampk modulators
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
TW200744586A (en) Therapeutic compounds
HK1133787A1 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
GEP20166443B (en) Heterocyclic compound and use thereof
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
NZ601350A (en) Method of treating arthritis
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
UA107562C2 (uk) Спосіб лікування псоріазу
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
TNSN08506A1 (en) Substituted carboxamides
MX2010003071A (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor.
EA201071369A1 (ru) Композиции для лечения выпадения волос
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
MX2009010164A (es) Metodo para tratar dolor mediado por el receptor cb2.
MX2012001449A (es) Inhibidores de cinasas c-jun-n-terminales (jnk).